ADC Linker and Payload Synthesis Capabilities

Antibody-drug conjugates (ADCs) are targeted medicines in which a monoclonal antibody is linked to a potent small-molecule drug through a chemical linker. Most ADCs developed so far treat cancer, and there is real potential in other diseases. The field is growing fast: as of June 2026, 23 ADCs had received regulatory approval worldwide, and more than 100 others are in development. After intravenous administration, the ADC binds its target antigen on the cancer cell and is internalized by receptor-mediated endocytosis. The linker then releases the cytotoxic payload, which triggers cell death. Because the antibody, linker and payload each affect efficacy and toxicity, optimizing every component while improving the ADC as a whole is one of the central challenges of ADC design.

The linker and the payload are small-molecule chemistry problems, and this is where AAPharmaSyn works. We provide ADC linker-payload synthesis for research and development programs, from individual linkers and payloads to complete linker-payload constructs.

Antibody-drug conjugate internalization and intracellular payload release pathway
Antibody-drug conjugate (ADC) icon showing an antibody with attached drug molecules

CIRCULATION

ADC solution is prepared and released into bloodstream

Challenge: A stable linker is required to limit non-target toxicity

ADC Linker Types Payload Release Mechanism

ADC Linker Technology

Release Mechanism

Designed to be cleaved through disulfide exchange with an intracellular thiol, such as glutathione

Designed for serum stability and degradation in acidic compartments within the cytoplasm

Non-cleavable. The payload is released after the antibody is degraded inside the lysosome

Designed to be cleaved by lysosomal proteases such as cathepsin B

Chemical diagram of a noncleavable ADC linker connecting an antibody to a cytotoxic payloadChemical structure of a maleimide-based linker joining an antibody to a cytotoxic payload
Chemical structures of cleavable antibody-drug conjugate linkers

Chemical Structures of non-cleavable and cleavable linkers. (A) SMCC linkers. (B) Maleimidocaproyl linker. (C) Protease cleavable peptide-based linker. (D) Reducible disulfide linker. (E) Acid-sensitive hydrazone linker. 

As of 2021 among the 114 completed or ongoing human trials, there is a lack of diversification in the medicinal payloads utilized, with only 7 payload preparations reported, (4 additional trials are ongoing with non-reported structures). Six of seven payload mixtures are derived from natural product sources, highlighting the value of natural products as cytotoxic payloads for ADC in research studies.
Most approved ADCs carry one of two kinds of payload. Tubulin inhibitors, such as the auristatins MMAE and MMAF and the maytansinoids, stop cancer cells from dividing. DNA-damaging agents, such as calicheamicins and pyrrolobenzodiazepines, kill cells independently of cell growth. Topoisomerase I inhibitors such as DXd and SN-38 now dominate late-stage development. Each payload brings its own chemistry, so the linker is usually designed around it.


Custom cytotoxic payloads for ADC Research. 
Custom cytotoxic payloads are an active area of ADC research. Contact us to discuss your payload or linker-payload target.

Chemical diagram of trastuzumab emtansine (Kadcyla) antibody-drug conjugate

Trastuzumab emtansine (Kadcyla) for treatment of HER2-positive breast cancer FDA-approved in 2013

Chemical diagram of gemtuzumab ozogamicin (Mylotarg) antibody-drug conjugate

Gemtuzumab ozogamicin (Mylotarg) for treatment of CD33-positive acute myelogenous leukemia FDA-approved in 2000; withdrawn in 2010

Chemical diagram of brentuximab vedotin (Adcetris) antibody-drug conjugate

Brentuximab vedotin (Adcetris) for treatment of CD30-positive relapsed or refractory Hodgkin's lymphoma FDA-approved in 2011